Octalfa
VC Fund
Écully, France
Octalfa is a France-based venture capital firm that offers a range of financial services.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Octalfa invests in
Stages Octalfa invests in
Countries Octalfa invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $658k–$4.6M
- Series A
- $1.5M–$3.7M
Investment Focus
Industry
- Biotechnology 9 (45%)
- Health Care 8 (40%)
- Medical 5 (25%)
- Pharmaceutical 3 (15%)
- Wellness 2 (10%)
Stage
- Funding Round 7 (35%)
- Seed 4 (20%)
- Series A 2 (10%)
- Series B 2 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Annie Beucler
Administrative Manager
|
Administrative Manager | Total investments: 0 | Find email | |
Gilles Alberici
President
|
President | Total investments: 1 | Find email | |
Jérémy Bastid
R&D Director
|
R&D Director | Total investments: 0 | Find email | |
Julien Alberici
Operations Manager
|
Operations Manager | Total investments: 1 | Find email | |
Laurence Simon
Administrative and Financial Director
|
Administrative and Financial Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kimialys
|
Kimialys develops and sells proprietary and patented surface chemistry for biosensors, increasing their sensitivity and specificity to deliver reliable, rapid, and cost-effective diagnostic tests. It was founded in 2020 by Cyril Gilbert and Claude Nogues in Paris, Ile-de-France, France. | $4.2M / Seed / Dec 05, 2025 | |
Sirius NeoSight
|
Sirius NeoSight is a biotech and pharmaceutical company that detects subclinical neo-cancers and provide treatment for it. | $4.6M / Seed / Feb 04, 2025 | |
ORPHELIA Pharma
|
ORPHELIA Pharma is a French pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases. ORPHELIA’s mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. We focus ondeveloping optimized formulations for the pediatric population of approved drugs as well as obtaining the approval for existing drugs in new pediatric orphan indications. | Dec 01, 2017 | |
Mathym
|
Mathym is a biomedical company that develops and supplies colloidal nanomaterials for dental applications. | $2.4M / Oct 17, 2016 | |
|
ORPHELIA Pharma
|
ORPHELIA Pharma is a French pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases. ORPHELIA’s mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. We focus ondeveloping optimized formulations for the pediatric population of approved drugs as well as obtaining the approval for existing drugs in new pediatric orphan indications. | Oct 09, 2015 | |
Amolyt Pharma
|
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $2M / Mar 17, 2015 | |
NightSwapping
|
NightSwapping is a community of over 150,000 members who swap nights to travel and stay for free at each other's places. With money out of the equation, hosts and travelers can enjoy a truly authentic experience with no legal issues. And when don't know where want to go, it's easy! Just let them surprise with suggestions ofunexpected & exciting destinations! | $2.2M / Seed / Sep 10, 2014 | |
|
Mathym
|
Mathym is a biomedical company that develops and supplies colloidal nanomaterials for dental applications. | $658K / Seed / Jun 30, 2014 | |
e(ye)BRAIN
|
e(ye)BRAIN is a medical company that manufactures and distributes eye trackers for its clients.e(ye)BRAIN’s range of products include Eye Brain T1 and T2. The T1 enables its users to record eye movements. T2 uses algorithms to enable its users to record eye and head movements. The recorded movements will be analyzed by a software called MeyeEval.The company offers advisory, paradigm development, formation, and support services to its clients.e(ye)BRAIN was founded in 2008 by Serge Kinkingnehun and is based in France. | $3.3M / Series B / Oct 09, 2012 | |
|
Amolyt Pharma
|
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $3.6M / Jun 04, 2012 | |
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Octalfa invest in?
Octalfa invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Seed stage. Most of the 20 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Octalfa's check size?
Octalfa typically joins rounds of $658k–$4.6M at Seed and $1.5M–$3.7M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Octalfa participates in.
How do I contact Octalfa?
Public channels for Octalfa include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Octalfa?
The team at Octalfa includes Annie Beucler (Administrative Manager), Gilles Alberici (President) and Jérémy Bastid (R&D Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
